Home / Stocks / Jenburkt Pharmaceutical L
JENBURPH

Jenburkt Pharmaceutical L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹900.3

Change

-24.15 (-2.61%)

Open

₹924.5

Prev. Close

₹924.45

Day High

₹932.95

Day Low

₹896.05

Volume Analysis

Traded

3,356

Delivered

2,711

Delivery %

80.78%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (26.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹960.39 ₹946.67 ₹923.49 ₹909.77 ₹886.59 ₹872.87 ₹849.69
Fibonacci ₹946.67 ₹932.57 ₹923.87 ₹909.77 ₹895.67 ₹886.97 ₹872.87
Camarilla ₹910.45 ₹907.07 ₹903.68 ₹909.77 ₹896.92 ₹893.54 ₹890.15

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-7.01%

1 Month

+0.96%

3 Months

-12.46%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

17.15%

Net margin 20.71% × asset turnover 0.72x × equity multiplier 1.15x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Jenburkt Pharmaceutical L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (20/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (26.0%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

70/100 — Good

Data confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

57

Cash Flow

50

Corporate Governance

76

Institutional Ownership

20

Business Quality

100

Risk & Volatility

54

Liquidity

50

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Publication for standalone Unaudited financial results for the quarter and half year ended on 30th September, 2026.

Jenburkt approved Q2 and H1 FY2026 standalone results; PAT rose to Rs 1,609.50 lakh.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 38 36 39 33 41 37 41 36 46 43 45 36 48
Expenses + 29 28 29 23 30 28 30 27 32 36 30 29 35
Operating Profit 9 7 10 9 11 9 11 9 13 7 14 6 13
OPM % 24.0% 20.0% 25.0% 29.0% 28.0% 24.0% 26.0% 25.0% 29.0% 17.0% 32.0% 17.0% 27.0%
Other Income + 1 1 1 1 2 2 2 2 2 2 0 2 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 10 8 10 10 13 10 12 10 14 8 14 7 14
Tax % 23.0% 31.0% 24.0% 26.0% 23.0% 32.0% 28.0% 23.0% 29.0% 29.0% 21.0% 13.0% 29.0%
Net Profit + 7 5 8 7 10 7 9 8 10 6 11 6 10
EPS in Rs 17 12 18 17 22 15 19 18 23 13 25 13 23
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 7 3 10 12 8 3 6 9 11 17 9 0 6

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 85 94 103 115 123 119 109 124 137 142 152 169
Expenses + 70 77 84 91 98 99 89 97 106 109 111 125
Operating Profit 15 16 20 24 25 20 20 27 30 33 40 44
OPM % 18.0% 18.0% 19.0% 21.0% 20.0% 17.0% 18.0% 22.0% 22.0% 23.0% 27.0% 26.0%
Other Income + 2 3 3 3 3 4 4 5 5 5 7 6
Interest 0 0 0 0 0 1 0 0 0 0 0 0
Depreciation 3 2 2 2 1 2 2 2 2 2 3 3
Profit before tax 14 17 20 25 27 21 22 30 33 35 44 47
Tax % 33.0% 36.0% 34.0% 32.0% 26.0% 30.0% 24.0% 25.0% 25.0% 26.0% 27.0% 25.0%
Net Profit + 10 11 14 17 20 15 16 22 25 26 32 35
EPS in Rs 21 23 29 38 43 32 36 49 56 59 73 79
Dividend Payout % 30.0% 31.0% 28.0% 24.0% 24.0% 25.0% 28.0% 25.0% 26.0% 26.0% 25.0% 26.0%
Sales growth 12 10 10 11 7 -3 -8 13 10 4 7 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 29 36 50 57 73 75 94 113 118 141 167 193 201
Borrowings + 7 5 6 0 7 3 5 7 3 0 4 2 2
Other Liabilities + 21 12 16 16 18 21 17 18 16 19 19 26 28
Total Liabilities 61 58 76 77 103 104 120 143 141 164 195 225 235
Fixed Assets + 12 12 11 10 10 12 11 11 10 10 15 19 74
CWIP 0 0 0 0 1 0 0 0 1 1 40 46 3
Investments 0 1 2 5 5 4 7 8 11 17 21 27 30
Other Assets + 49 45 64 62 87 88 103 123 119 136 120 132 128
Total Assets 61 58 76 77 103 104 120 143 141 164 195 225 235
Equity Capital 5 5 5 5 5 5 5 5 4 4 4 4 4

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 9 8 10 16 13 15 19 9 17 8 28 27
Cash from Investing Activity + 1 0 -10 1 -11 -3 -19 -1 3 -1 -17 -19
Cash from Financing Activity + 1 -5 1 -18 -2 -11 -1 -6 -21 -7 -8 -9
Net Cash Flow 11 2 1 -1 0 1 0 3 -1 0 3 -2
Free Cash Flow 8 5 10 16 11 11 18 7 15 6 8 13
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 88 82 85 103 80 104 127 62 83 49 102 88

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 47.39% → 46.62%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 52.63% 52.78% 53.29% 53.28% 53.2% 53.2% 53.21% 53.22% 53.24% 53.24% 53.27% 53.34%
Promoters 47.39% 47.23% 46.71% 46.71% 46.69% 46.68% 46.67% 46.66% 46.65% 46.64% 46.62% 46.62%
DII 0.0% 0.0% 0.0% 0.0% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.03%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Jenburkt Pharmaceutical L (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Jenburkt Pharmaceutical L?

Frequently Asked Questions about Jenburkt Pharmaceutical L

Community Sentiment

What are other investors saying about Jenburkt Pharmaceutical L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.